Detalhe da pesquisa
1.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(5): 655-663, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32251621
2.
Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.
Genet Med
; 19(7): 787-795, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28125075
3.
Genetic modifiers of EGFR dependence in non-small cell lung cancer.
Proc Natl Acad Sci U S A
; 111(52): 18661-6, 2014 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25512530
4.
Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside".
Biochemistry
; 58(12): 1555-1557, 2019 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30865435
5.
A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition.
NPJ Precis Oncol
; 8(1): 3, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38182677
6.
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Blood
; 117(9): 2567-76, 2011 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21068437
7.
WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion.
Nat Genet
; 35(4): 372-6, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14608358
8.
Administration of vincristine in a patient with Machado-Joseph disease.
Oncology
; 82(3): 165-7, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22433430
9.
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
Clin Cancer Res
; 28(14): 3091-3103, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247929
10.
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
JMIR Cancer
; 8(2): e33859, 2022 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35588361
11.
ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation.
Cancer Discov
; 8(6): 676-678, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29858224
12.
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
Clin Cancer Res
; 24(23): 5963-5976, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30072474
13.
Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch.
Trends Endocrinol Metab
; 16(3): 98-103, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15808806
14.
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Science
; 351(6278): 1214-8, 2016 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26912360
15.
A functional landscape of resistance to ALK inhibition in lung cancer.
Cancer Cell
; 27(3): 397-408, 2015 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25759024
16.
An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis.
Proc Natl Acad Sci U S A
; 104(10): 4025-9, 2007 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-17360471
17.
WNK4 regulates activity of the epithelial Na+ channel in vitro and in vivo.
Proc Natl Acad Sci U S A
; 104(10): 4020-4, 2007 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-17360470
18.
WNK3, a kinase related to genes mutated in hereditary hypertension with hyperkalaemia, regulates the K+ channel ROMK1 (Kir1.1).
J Physiol
; 571(Pt 2): 275-86, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16357011
19.
WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis.
Proc Natl Acad Sci U S A
; 102(46): 16777-82, 2005 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16275913
20.
WNK kinases: molecular regulators of integrated epithelial ion transport.
Curr Opin Nephrol Hypertens
; 13(5): 557-62, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15300163